1. Volume 16, Issue 6, Pages 569-579.e1 (June 2015)
A Retrospective Cohort Study of Long-Term Immediate-Release Hydrocodone/Acetaminophen Use and Acetaminophen Dosing Above the Food and Drug Administration Recommended Maximum Daily Limit Among Commercially Insured Individuals in the United States (2008–2013) 
Angela DeVeaugh-Geiss, Aditi Kadakia, Howard Chilcoat, Louis Alexander, Paul Coplan 
The Journal of Pain 
Volume 16, Issue 6, Pages e1 (June 2015)
DOI: /j.jpain
Copyright © 2015 The Authors Terms and Conditions

2. Figure 1
Number (A) and percentage (B) of patients initiating each drug receiving long-term (>90 days) treatment using a 15- and 30-day allowable gap.
The Journal of Pain  , e1DOI: ( /j.jpain )
Copyright © 2015 The Authors Terms and Conditions

3. Figure 2
Number of patients in each opioid dose category at month 4 of long-term treatment (among patients treated >90 days only).
The Journal of Pain  , e1DOI: ( /j.jpain )
Copyright © 2015 The Authors Terms and Conditions

4. Figure 3
Distribution of total acetaminophen dose during IR hydrocodone/acetaminophen treatment (total person-time of exposure = 48,615,038 days).
The Journal of Pain  , e1DOI: ( /j.jpain )
Copyright © 2015 The Authors Terms and Conditions